Replies to post #430266 on NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

$62.

[dude409]

73.47

[CaptainObvious]

$42.xx

[hope4patients]

$46.25

[The Danish Dude]

Not a bad guess.

I’m getting more and more confident, that BP haven’t got the money to make the proverbial offer NWBO can not refuse. The longer NWBO manages to build up infrastructure and patent portfolio without an offer, the more the SP will go up in the wake of TLD, journal and uplisting.

If not BO before years end at $28-30, I will think partnership and an SP in the mid 20’s is reasonable.

[Pharmboy46]

$15.00

[Maverick0408]

I think they will be bought out for around $20 before the end of 2022.

[StonkMaster]

$34.88

[Sir Pumpernickel]

0

[jman4956]

$23 but I’m hoping to sell a few in the $40’s before it settles down.

[hoffmann6383]

$10-15 buyout (market cap @ $12.5-17.5B). Otherwise, $2.50 if no b/o.

3-5 years $40B market cap. Very optimistic but after looking at NVCR's timeline today, we still have a long ways to go for all the regulatory approvals, insurance reimbursement negotiations, healthcare adoption, manufacturing capacity, etc. 2022 I see as a transformational year but stock appreciation might lag what we think to be the FMV. An uplisting will be key to seeing huge numbers in 22 and I'm still not certain what is required for an uplisting.

[The Rover 64]

$27.83

[TiltMyBrain]

12.99

Oh wait. That is for a pound of hamburger

[HappyLibrarian]

More still, will NWBO actually give a concrete and unambiguous update on the core issues (TLD etc.) by the ASM in 2022?

[Kam8]

$22

[flipper44]

Depends on flaskworks timing and result strength. Without a reverse split, I’d say the range is 23.00 upwards to 73.00.

[Chiugray]

My guess, $50/sh by 1/1/2023, assuming approval and a partnership.

Because approval means
- DCVax-L gains steady adoption on a country by country basis globally during the next 12 months as the best-in-class, first line, standard of care treatment for GBM
- DCVax is validated as the safe, efficacious, autologous immunotherapy platform.
- DCVax-Direct narrative as a possible disrupter to current solid tumor cancer drug companies gets legs, so the market cap then begins to reflect this valuation because it is currently not.

Because Partnership means
- A strategic decision was made that Big Pharma will end up paying manyfold more in a buyout a couple years later, than now. Because by then, all will know and shall bow to the dendritic cell and immune system.
- It is not a “go-it-alone” but rather a gain-commercial-partner strategy.
- Maybe a partnership strategy for DCVax-Direct, in the same way Merck licenses Keytruda for combination treatment clinical trial studies, as in 200 clinical trials across 30 tumor types.

[br8k0ut]

Buyout somewhere in 2022 between $33-$35

[joeycav11]

19.88

[Know-Fear]

January 1st is a market holiday and also falls on a Sunday in 2023. So essentially your asking for the market close price on Friday 12/30/22. The irreverent side of me wants to go with .875 (before someone else does)…..so I’ll go with the .875 with a 12.30 multiplier.

[eagle8]

100+ ( Direct involved imo ).

[scotty3371]

4.50-5.00

[Mionaer1]

BO at $14 per share next year.

[Hopeforthefuture3]

Gary, I'll go with $7 per share based on good data published first half of 2022 and by second half of 2022 will have submitted bla and waiting for regulatory approval sometime in 2023. This is up 10x from current price
Good luck

[sukus]

$10 - $12.

[X Master]

peaking at 35 coming back to 27.50 and then trending up.

[martyDg]

Between .22 and 12

[branster]

skitahoe, due to the pace NWBO treads at I suspect a good POP of the SP to $3-5 bucks then settle back around $2 by end of 2022. Being it seems we will between .50 and .70 cents before TLD hits a 5 to 10X is all I expect.
There I no way I see approval by 2023.

[StockFollower]

$66.66

[H2R]

$17

Best of luck to Patients, NWBO, and Longs!

[Enoch_365]

Based on RA Approvals by mid-year
and publication and TLD by Spring;
and then uplisting to New York Stock Exchange or NASDAQ by Summer -

range at end of year 2022 ..... $6 to $15 .....

biggest unknown based on those assumptions is how quickly manufacturing can meet regulatory and demand ...
above assumes fully diluted number of shares of stock and no issuance of additional new shares

[exwannabe]

As long as we have a full set of players I will join in.

$0.31 based on following the present downtrend and no real news. Manufacturing will continue on course, but revenue will be nothing significant.

NOTE: I doubt any sort of change of control happens this year. If so, I am using whatever the EOY value of the deal is. I put the odds on this as less than 5%.

[skitahoe]

For those who answered this post previously, thanks and this weekend I'll summarize your predictions. For those who haven't answered, if you like to, please do so by the end of the year and I'll happily include you. If you provided a range, I'd prefer a single number, so feel free to revise, but if not, I'll include your range.

I do believe that next year will be far more financially rewarding for NWBO, and biotech investors in general. I believe that this year has been rather weak for biotech's in general, but next year offers the promise of approval for ours, and many other products in the pipeline, it could be the best year for biotech's in quite awhile.

Happy New Year's,

Gary

[skitahoe]

I noted recently that the JP Morgan Healthcare Conference in early January has become a virtual one, I'm wondering if the upcoming conference where Dr. Bosch should be presenting, and others where NWBO may present, or have a booth, are following JP Morgan's lead.

I would hope that next year's ASCO could get a presentation by the company, though it may be difficult after a Journal. One possibility could be to discuss how patients alive at the time the Journal is based on are doing today.

Gary

[hump4]

$80. The run up will cause a massive short squeeze.

[hoffmann6383]

$12.5

revising my earlier post since I gave 3 numbers.

[MI Dendream]

Gary, There are questions for me which drives this number.

With three quarters of data, but only two reported, will they provide us number of patients in addition to revenue? How quickly can institutions change protocols to allow for tissue to be properly packaged and sent out (Did LL’s call to arms get anyone ready? I am guessing no here)? Will we get all four reg approvals in Q1? Is there a partnership or take over?

My guesses are, yes, about 2-3 months in most cases so it will be a slow start, No again, yes, and partnership.

My answer is… We spike much higher, then fall, then recover ground so that 1/1/23 we start at $14.75 with momentum building throughout that year.

[Bigmahalo]

$11.45
I too believe there will be a higher price and then a pull back as we wait for more deadlines to be met.
Gary, thanks for doing the survey :)
Happy New Year all.

And enjoy this race...

😂😂 pic.twitter.com/TT4MUeuqpN

— Richard Marx (@richardmarx) December 24, 2021

[Palmer50]

Approval and buyout $28

[ccie1024]

Gary -

$8.33340

Gonna go out on a limb here and say we move at a slower pace than most would prefer.

Happy to be wrong.

But by that time I will have formally validated my model of financial independence and be well on the way to implementing it.

ccie

[voloda69]

$69

[Lorie3168]

My number is based on a complete buyout
$47.

[ou71764]

For the fun of it, let's all guess at what we believe the stock price will be on January 1st, 2023. If you wish you may add your assumptions along with the price.

I'll say .35 with the idea they'll need to due a major dilution in order to restart the trial.

[abc1212]

For a long time thought, with TLD and publication out, and with a BLA submitted, which should all be done in 2022, the SP would be somewhere between $30 - $35

To pick a price, $33

Cheers for doing this Gary and good luck to all longs

[10baggerz]

So many variables in terms of timing. I think we get TLD, publication, MHRA approval and FDA BLA submission by 2023.
$8.25
A more specifc question would be what is the market cap and I think it will be about $14 billion

[BigAl2020]

$25

[snowmonkey117]

$17

[sun bum]

I'll guess $11

[veeets]

$88. Thanks.

Hi, Direct reply (no pun intended) lol.